Abstract This 2022 European Atherosclerosis Society lipoprotein (a)[Lp (a)] consensus
statement updates evidence for the role of Lp (a) in atherosclerotic cardiovascular disease …

Rates of atherosclerotic cardiovascular diseases (CVD) in the Western world have
spectacularly decreased over the past 50 years. However, a substantial proportion of high …

Abstract Lipoprotein (a)[Lp (a)] became besides LDL cholesterol one of the most attractive
targets for intervention in cardiovascular disease. Strong genetic evidence supports the …

Abstract Lipoprotein (a)[Lp (a)] is a source of residual risk in patients with atherosclerotic
cardiovascular disease (ASCVD). Clinical trials of fully human monoclonal antibodies …

Abstract In 2022, the European Atherosclerosis Society (EAS) published a new consensus
statement on lipoprotein (a)[Lp (a)], summarizing current knowledge about its causal …

Background Elevated lipoprotein (a) and familial hypercholesterolaemia are both
independent risk conditions for cardiovascular disease. Although signs of atherosclerosis …

The initial studies focusing on lipoprotein (a)[Lp (a)] and its role in atherosclerotic
cardiovascular disease were conducted exclusively in Whites. Subsequently, multiple large …

Since the contribution of high Lp (a) concentrations to global ASCVD risk has been
underestimated in the past, a clear recommendation to measure Lp (a) at least once in a …

Lp (a) and diabetes are both known and established risk factors for the development of
cardiovascular disease. However, studies trying to link both risk factors find an inverse …

Abstract Lipoprotein (a)[Lp (a)], a distinct lipoprotein class, has become a major focus for
cardiovascular research. This review is written in light of the recent guideline and consensus …